Mangoceuticals Statistics
Share Statistics
Mangoceuticals has 2.49M shares outstanding. The number of shares has increased by -89.17% in one year.
| Shares Outstanding | 2.49M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -91.69% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.74M |
| Failed to Deliver (FTD) Shares | 415 |
| FTD / Avg. Volume | 0.24% |
Short Selling Information
The latest short interest is 194.40K, so 7.82% of the outstanding shares have been sold short.
| Short Interest | 194.40K |
| Short % of Shares Out | 7.82% |
| Short % of Float | 11.18% |
| Short Ratio (days to cover) | 0.21 |
Valuation Ratios
The PE ratio is -0.64 and the forward PE ratio is null.
| PE Ratio | -0.64 |
| Forward PE | null |
| PS Ratio | 8.1 |
| Forward PS | null |
| PB Ratio | 7.65 |
| P/FCF Ratio | -0.85 |
| PEG Ratio | n/a |
Enterprise Valuation
Mangoceuticals Inc. has an Enterprise Value (EV) of 5.32M.
| EV / Earnings | -0.58 |
| EV / Sales | 7.27 |
| EV / EBITDA | -0.58 |
| EV / EBIT | -0.58 |
| EV / FCF | -0.76 |
Financial Position
The company has a current ratio of 3.88, with a Debt / Equity ratio of 0.
| Current Ratio | 3.88 |
| Quick Ratio | 3.79 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -11.89% and return on capital (ROIC) is -1020.43%.
| Return on Equity (ROE) | -11.89% |
| Return on Assets (ROA) | -8.77% |
| Return on Capital (ROIC) | -1020.43% |
| Revenue Per Employee | 243.83K |
| Profits Per Employee | -3.07M |
| Employee Count | 3 |
| Asset Turnover | 0.7 |
| Inventory Turnover | 16.21 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -45.34% in the last 52 weeks. The beta is 0, so Mangoceuticals 's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | -45.34% |
| 50-Day Moving Average | 2.49 |
| 200-Day Moving Average | 3.93 |
| Relative Strength Index (RSI) | 50.98 |
| Average Volume (20 Days) | 170.93K |
Income Statement
In the last 12 months, Mangoceuticals had revenue of 731.49K and earned -9.21M in profits. Earnings per share was -6.45.
| Revenue | 731.49K |
| Gross Profit | 431.50K |
| Operating Income | -9.22M |
| Net Income | -9.21M |
| EBITDA | -9.19M |
| EBIT | -9.22M |
| Earnings Per Share (EPS) | -6.45 |
Balance Sheet
The company has 739.01K in cash and 128.68K in debt, giving a net cash position of 610.33K.
| Cash & Cash Equivalents | 739.01K |
| Total Debt | 128.68K |
| Net Cash | 610.33K |
| Retained Earnings | -11.23M |
| Total Assets | 14.79M |
| Working Capital | -1.29M |
Cash Flow
In the last 12 months, operating cash flow was -7.00M and capital expenditures -3.52K, giving a free cash flow of -7.00M.
| Operating Cash Flow | -7.00M |
| Capital Expenditures | -3.52K |
| Free Cash Flow | -7.00M |
| FCF Per Share | -4.9 |
Margins
Gross margin is 58.99%, with operating and profit margins of -1.26K% and -1.26K%.
| Gross Margin | 58.99% |
| Operating Margin | -1.26K% |
| Pretax Margin | -1.26K% |
| Profit Margin | -1.26K% |
| EBITDA Margin | -1.26K% |
| EBIT Margin | -1.26K% |
| FCF Margin | -957.07% |
Dividends & Yields
MGRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -250% |
| FCF Yield | -109.13% |
Analyst Forecast
Currently there are no analyst rating for MGRX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Oct 16, 2024. It was a backward split with a ratio of 1:15.
| Last Split Date | Oct 16, 2024 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -1.01 |
| Piotroski F-Score | 4 |